In addition to the association between CLL aggressiveness and RRAS2 expression in patients, we found another powerful correlation in human disease that sustains our hypothesis suggesting RRAS2 overexpression is one of the key driver oncogenes in CLL. This evidence concerns the gene RRAS2 and B-cell chronic lymphocytic leukemia.